An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin's Disease
Latest Information Update: 06 Sep 2019
At a glance
- Drugs Iratumumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Medarex
Most Recent Events
- 06 Sep 2019 New trial record